David M Jackman

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Current options for systemic therapy in mesothelioma
    David M Jackman
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Semin Thorac Cardiovasc Surg 21:154-8. 2009
  2. ncbi request reprint Small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 366:1385-96. 2005
  3. pmc Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials
    David M Jackman
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:5267-73. 2009
  4. pmc The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations
    Stephanie Heon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 18:4406-14. 2012
  5. pmc New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02116, USA
    AJR Am J Roentgenol 195:W221-8. 2010
  6. pmc Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib
    Stephanie Heon
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:5873-82. 2010
  7. pmc Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
    Daniel B Costa
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7060-7. 2008
  8. pmc Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 79:283-8. 2013
  9. ncbi request reprint Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    David M Jackman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:4517-20. 2006
  10. pmc Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Thorac Oncol 8:1059-68. 2013

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Current options for systemic therapy in mesothelioma
    David M Jackman
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Semin Thorac Cardiovasc Surg 21:154-8. 2009
    ..This article surveys the current clinical landscape of systemic therapies in mesothelioma and explores the impact of both conventional and targeted agents...
  2. ncbi request reprint Small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 366:1385-96. 2005
    ..For patients who survive long term, careful monitoring for development of a second primary tumour is necessary, with further investigation and treatment as appropriate...
  3. pmc Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials
    David M Jackman
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:5267-73. 2009
    ....
  4. pmc The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations
    Stephanie Heon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 18:4406-14. 2012
    ....
  5. pmc New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02116, USA
    AJR Am J Roentgenol 195:W221-8. 2010
    ..1) to the original guidelines (RECIST 1.0) for advanced non-small cell lung cancer (NSCLC) after erlotinib therapy and to evaluate the impact of the new CT tumor measurement guideline on response assessment...
  6. pmc Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib
    Stephanie Heon
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:5873-82. 2010
    ..However, there are incomplete data about their impact on the development and control of CNS metastases...
  7. pmc Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
    Daniel B Costa
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7060-7. 2008
    ..Our goal was to determine the effects of erlotinib 150 mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib is given at a higher biologically active dose than gefitinib...
  8. pmc Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 79:283-8. 2013
    ..TKIs are often continued beyond progressive disease by RECIST. We investigated the practice of continuing EGFR-TKIs after RECIST-PD via CT findings...
  9. ncbi request reprint Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    David M Jackman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:4517-20. 2006
  10. pmc Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Thorac Oncol 8:1059-68. 2013
    ....
  11. pmc Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
    ..Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies...
  12. pmc The introduction of systematic genomic testing for patients with non-small-cell lung cancer
    Stephanie Cardarella
    Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Thorac Oncol 7:1767-74. 2012
    ..We report the implementation of systematic prospective genotyping for somatic alterations in BRAF, PIK3CA, HER2, and ALK, in addition to EGFR and KRAS, in NSCLC patients at the Dana-Farber Cancer Institute...
  13. pmc EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry
    Lynette M Sholl
    Department of Pathology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Am J Clin Pathol 133:922-34. 2010
    ..Thus, EGFR sequence analysis was the only method useful for predicting response and progression-free survival following TKI therapy in NSCLC...
  14. doi request reprint Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
    David M Jackman
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:808-14. 2008
    ..These agents have activity in non-small cell lung cancer, but their role in mesothelioma is unclear. The primary endpoint is response rate. Secondary endpoints include time to progression, survival, and toxicity...
  15. ncbi request reprint Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:760-6. 2007
    ..The secondary end points include radiographic response rate, time to progression (TTP), toxicity, and symptom improvement...
  16. pmc Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers
    Kimio Yonesaka
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:6963-73. 2008
    ..The determinant(s) of efficacy of EGFR-targeted therapies in EGFR wild-type cancers is not well defined...
  17. ncbi request reprint Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    David M Jackman
    Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3908-14. 2006
    ..Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib...
  18. pmc Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute and Brigham and Womens Hospital, Boston, MA 02215 5450, USA
    Cancer Imaging 12:225-35. 2012
    ....
  19. pmc Imaging of lung cancer in the era of molecular medicine
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Acad Radiol 18:424-36. 2011
    ..Knowledge of the molecular basis of lung cancer is essential for radiologists to properly interpret imaging and assess response to therapy. Quantitative and functional imaging helps assessing the biologic behavior of lung cancer...
  20. doi request reprint Treatment of peritoneal mesothelioma in pediatric patients
    Leigh Anne Cioffredi
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:127-9. 2009
    ..Treatment was well tolerated, and three of these patients have achieved long-term survival. The fathers of three of the patients worked in the construction industry and may have been the source of indirect asbestos exposure...
  21. pmc Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC
    Raymond H Mak
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Oncologist 16:886-95. 2011
    ..Epidermal growth factor receptor (EGFR) mutations identify a unique biological subtype of non-small cell lung cancer (NSCLC). Treatment outcomes for EGFR-mutant locally advanced NSCLC patients have not been well described...
  22. pmc Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Oncologist 18:1214-20. 2013
    ..We observed an improved response rate but no difference in progression-free survival or overall survival. A larger prospective clinical trial is needed to evaluate this promising strategy further. ..
  23. ncbi request reprint Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment
    David M Jackman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Respir Crit Care Med 26:342-52. 2005
    ..This article reviews the epidemiology, risk factors, pathology, clinical presentation, and treatment of this disease. Special focus is paid to the emerging role of oral EGFR-TKIs in Bronchioloalveolar cell carcinoma...
  24. pmc CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Acad Radiol 18:54-62. 2011
    ..Determine inter- and intraobserver variability of computed tomography (CT) tumor volume measurements in advanced non-small-cell lung cancer (NSCLC) patients treated in a Phase II clinical trial using chest CT...
  25. doi request reprint Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
    Geoffrey R Oxnard
    Authors Affiliations Department of Medical Oncology Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 20:1698-705. 2014
    ..We sought to determine whether droplet digital PCR (ddPCR) of cfDNA would allow highly specific and quantitative assessment of tumor genotype...
  26. pmc Pathologic characteristics of NUT midline carcinoma arising in the mediastinum
    Andrew G Evans
    Department of Pathology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Surg Pathol 36:1222-7. 2012
    ..NMC should be considered in the differential diagnosis of any poorly differentiated epithelioid mediastinal tumor, regardless of age...
  27. ncbi request reprint Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 107:975-81. 2006
    ..To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC...